Original Title: A Study of a Psilocybin Analog (CYB003) in Participants With Major Depressive Disorder
Topic Depression
Compound Psilocybin
Country Canada
Visit trial
Status
Not yet recruiting
Results Published
No
Start date
19 July 2022
End date
23 July 2023
Chance of happening
89%
Phase
Phase I
Phase II
Design
Blinded
Type
Interventional
Generation
Second
Participants
40
Sex
All
Age
21- 55
Therapy
No
Trial Details
NCT Number NCT05385783
Sponsors & Collaborators
CybinCybin is a for-profit company that aims to deliver psychedelics (psilocybin) via a sublingual delivery mechanism. The company aims to start clinical trials within the year (2021). It has raised $98 million US.